Interferon gamma release assay

Fact Sheets Testing & Diagnosis Fact Sheet - Recommendations for Human

Interferon-gamma release assays (IGRAs) are blood- based tests that measure the amount of interferon-gamma released by T lymphocytes after stimulation by antigens specific for M. tuberculosis. IGRAs are not recommended for diagnosis of active pulmonary tuberculosis because they cannot distinguish between latent tuberculosis infectio Ifn Gamma Release Assay; Interferon-Gamma (Ifn-Γ) Release Assay; Ige Antibody Release Histamines; Pam3Csk4-Induced Tnfa Release In Thp-1 Cells; Reagecon Co2 Release Reagent; Psa Assay Reliability; Igg Antibody Reliability; Elisa Testing Reliability Hsv; Sars Antigen Reliable; Is Zonulin Reliable; Igg Antibody Reliable OBJECTIVES: To assess the utility of interferon-gamma (IFNγ)-release assay with a prolonged follow-up in preventing unnecessary anti-TB therapy in individuals with suspected false positive results. METHODS: Between 2008 and 2012 the QuantiFERON TB gold-in-tube test (QFT-G) was performed in 278 sequential individuals who were mostly TST-positive and/or were in contact with an active TB patient The IFN-γ release assays (IGRA) are commonly used clinical tests to assess the likelihood of TB infection. The tests rely on the fact that memory T-lymphocytes generated after exposure to TB release IFN-γ upon re-exposure to TB antigens

These tests, which are collectively known as interferon gamma release assays (IGRAs), detect latent tuberculosis infection (LTBI) by measuring interferon (IFN)-γ release in response to antigens present in Mycobacterium tuberculosis, but not bacille Calmette-Guerin (BCG) vaccine and most nontuberculous mycobacteria QFT is an interferon-gamma (IFN-γ) release assay, commonly known as an IGRA, and is a modern alternative to the tuberculin skin test (TST, PPD or Mantoux). Unlike the TST, QFT is a controlled laboratory test that requires only one patient visit and is unaffected by previous Bacille Calmette-Guerin (BCG) vaccination Alternatives to the TST are T-cell-based interferon-gamma release assays (IGRAs). Two forms of IGRAs are currently available for commercial use that are widely used: QuantiFERON TB Gold in tube (QFT-GIT) and T-SPOT.TB. IGRAs have several advantages over TST such as higher specificity for Mtb and lack of cross reaction with BCG vaccination

Interferon gamma release assays: principles and practic

Interferon Gamma Release Assay - an overview ScienceDirect Topic

Interferon-gamma release assays (IGRAs), including the commercially available assays QuantiFERON-TB Gold In Tube (QFT-GIT; Qiagen, Hilden, Germany), and the T-SPOT.TB (Oxford Immunotec, Oxfordshire, UK), are used as alternatives to TST in settings where higher test acquisition costs can be supported The Interferon Gamma Release Assay (IGRA) is a blood test used to se e whether a person has been infected with . Mycobacterium tuberculosis (the bacteria causing TB) . The IGRA test works by measuring the body's immune response to the TB bacteria. An IGRA test may be used to diagnose latent TB infection Interferon-γ release assays Interferon-γ (interferon-gamma) release assays (IGRAs) are relatively new tests for tuberculosis. IGRAs are based on the ability of the Mycobacterium tuberculosis antigens for early secretory antigen target 6 (ESAT-6) and culture filtrate protein 10 (CFP-10) to stimulate host production of interferon-gamma Interferon-γ release assays (IGRAs) are blood tests that measure ex vivo T-lymphocyte release of interferon-γ after stimulation by antigens specific for M tuberculosis . Because these antigens are not found on M bovis -BCG or most nontuberculous mycobacteria, IGRAs are more specific tests than the TST, yielding fewer false-positive results

Interferon Gamma Release Assay - Interferon

  1. Recently, the interferon-gamma release assays (IGRAs) are being used increasingly to detect IFN-γ response of effector T cells to the mycobacterium tuberculosis-specific antigens, early secretary antigenic target 6 (ESAT-6), and culture filtrate protein 10 (CFP-10)
  2. Interferon-Gamma Release Assays (IGRAs) are in vitro blood tests of cell-mediated immune response that aids in the diagnosis of Mycobacterium tuberculosis infection. IGRA test for TB measures the T cell release of interferon (IFN) -gamma after being stimulated by antigens unique to Mycobacterium tuberculosis bacterium
  3. Interferon-γ release assays (IGRA) là các xét nghiệm y học được sử dụng trong chẩn đoán một số bệnh truyền nhiễm, đặc biệt là bệnh lao. Interferon-γ (IFN-γ) release assays dựa vào thực tế là các tế bào lympho T sẽ giải phóng IFN-γ khi tiếp xúc với các kháng nguyên đặc trưng
  4. Interferon-gamma release assays (IGRAs) are now increasingly being used for diagnosis of LTBI, but their role in HCW screening is unclear. A systematic review was conducted of all IGRA studies in HCWs to summarise their performance in cross-sectional and serial testing settings
  5. Tuberculosis Interferon Gamma Release Assay . Download Requisition Print Test. Collection/Transport. Collect. Green top tube (sodium heparin) Specimen Preparation. Do NOT centrifuge! Keep at room temperature (18-22°C). Preferred volume: 10 mL. Pediatric Collection. Minimum volume: 6 mL. Unacceptable Conditions
  6. Objective. To investigate the diagnostic value of interferon-gamma release assays combined with multiple indicators for tuberculous peritonitis. Methods. Patients who were admitted to the hospital due to suspected tuberculous peritonitis were prospectively included during the 30-month study period. Moreover, healthy individuals were recruited and included in the control group

Ifn Gamma Release Assay - Interferon

Interferon-gamma release assays (IGRAs) are blood tests that measure a person's immune reactivity to M. tuberculosis.. There are two IGRA tests available in the United States: • QuantiFERON®-TB Gold In-Tube (QFT-GIT) • T-SPOT®. T Interferon Gamma Release Assay. IGRAs are in vitro blood tests based on interferon-gamma release after stimulation by antigens such as Early Secreted Antigenic Target-6 (ESAT-6) and Culture Filtrate Protein-10 (CFP-10). From: The Microbiology of Respiratory System Infections, 2016 Related terms The main search concepts were the interferon gamma release assay and people in rural and remote settings who may have been exposed to tuberculosis. Where possible, retrieval was limited to the human population. The search was also limited to English-language documents published between January 1, 2015 and July 26, 2020 Interferon-gamma release assays are being increasingly used worldwide for the diagnosis of latent tuberculosis (TB) in patients of all ages, including children [].A PubMed search with 'interferon-gamma release assays' as keyword revealed a total of 1077 references, up to 100 of which had been released in 2012, including several reviews

A novel interferon-γ release assay for detection of SARS-CoV-2 specific T-cell response Download PDF Copy By Dr. Priyom Bose, Ph.D. Jul 26 2021 Reviewed by Benedette Cuffari, M.Sc Background The reliable detection of the T-cell mediated response to COVID-19 or COVID-19 vaccination is important for individual patient care and for monitoring the immune response e.g. in COVID-19 vaccine trials in a standardized fashion. Methods We used blood samples from health care workers (HCW) with or without history of COVID-19 to define test accuracy of a novel interferon-release assay Tuberculosis (TB)-associated uveitis is a common cause of infectious uveitis in the developing world. Diagnosis of TB uveitis remains a challenge. The role of interferon gamma release assays (IGRAs) is uncertain. Herein we summarise the available literature on the utility of IGRAs in the diagnosis and management of TB uveitis. We searched PubMed database from 1 August 2010 to 31 July 2020.

Recognition that interferon gamma (IFN-γ) plays a critical role in regulating cell-mediated immune responses to M. tuberculosis infection led to development of interferon gamma release assays (IGRAs) for the detection of M. tuberculosis infection (2--4) We performed a prospective multicentre diagnostic study to evaluate the combined interferon-γ (IFN-γ) and interleukin-2 (IL-2) release assay for detect active pulmonary tuberculosis (TB) in China. Adult patients presenting symptoms suggestive of pulmonary TB were consecutively enrolled in three TB-specialized hospitals

Interferon-gamma-release assay prevents unnecessary tuberculosis therapy

sequencing, or the interferon-gamma (IFN) release assay (IGRA) [2]. Initially established for diagnosing tuberculosis (TB) in cattle where tuberculin skin testing failed to identify all infected animals [3], the IGRA has since been adapted for the diagnosis of TB in other species [4,5], including cats [6]. These assays detect th Interferon gamma release assays, the second category of screening tests for TB infection, were designed at least in part to address these limitations of TST. They are in vitro blood tests that are now recommended by the Centers for Disease Control and Prevention as an aid in diagnosing infection with M. tuberculosis A novel interferon-γ release assay for detection of SARS-CoV-2 specific T-cell response Posted on 07/27/2021 Previous research using animal models has indicated the importance of T‐cells, particularly CD4+ and CD8+ T-cells, in protecting individuals against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the virus responsible for the coronavirus disease 2019. Interferon-Gamma Release Assay (Modified QuantiFERON) as a Potential Marker of Infection for Leishmania donovani, a Proof of Concept Study Kamlesh Gidwani1, Stephen Jones2, Rajiv Kumar1, Marleen Boelaert3, Shyam Sundar1* 1 Banaras Hindu University, Varanasi, India, 2 Cellestis limited, Chadstone, Victoria, Australia, 3 Institute of Tropical Medicine, Antwerp, Belgium Abstract Background: In. Background: Interferon Gamma Release Assays (IGRAs) are used to detect latent Mycobacterium tuberculosis (M.tb) infection (LTBI) in adults, but their performance in the elderly is not well-established.We evaluated IGRAs for LTBI detection in Hispanic elderly recent TB contacts (ReC) or community controls (CoC)

interferon-gamma release assay as a novel biomarker in systemic lupus erythematosus

Until recently, the only tool available to detect latent tuberculosis infection (LTBI) was the tuberculin skin test (TST). Although the TST has proven to be useful in clinical practice, it has known limitations [].An important advance in recent years has been the development of in vitro T cell—based IFN-γ release assays (IGRAs) Interferon Gamma Release Assay Myanmar; Nhp Interferon-Gamma Release Assay (Primagam). Use of interferon-gamma release assays in a health care worker screening program: experience from a tertiary care centre in the United States. Can Respir J 2012; 19:84. Pai M, Elwood K. Interferon-gamma release assays for screening of health care workers in low tuberculosis incidence settings: dynamic patterns and interpretational challenges Performance of interferon-gamma release assays (IGRAs) is influenced by preanalytical, laboratory and host factors. The data regarding how critical illnesses influence IGRA results are limited.

Interferon gamma (IFNγ) is a dimerized soluble cytokine that is the only member of the type II class of interferons. The existence of this interferon, which early in its history was known as immune interferon, was described by E. F. Wheelock as a product of human leukocytes stimulated with phytohemagglutinin, and by others as a product of antigen-stimulated lymphocytes Diagnosis of latent tuberculosis infection (LTBI) should be targeted toward individuals and groups with high risk of progression to active tuberculosis (TB). Low-risk populations should not be screened. Interferon-gamma release assays (IGRAs) perform as well or better than the tuberculin skin test in most targeted populations. IGRAs are preferred for bacille Calmette-Guérin (BCG)-vaccinated.

The role of interferon gamma release assays (IGRAs), although established for identifying latent tuberculosis, is still evolving in the diagnosis of active extrapulmonary tuberculosis. We systematically evaluated the diagnostic performance of blood- and pleural fluid-based IGRAs in tuberculous pleural effusion (TPE). We searched the PubMed and Embase databases for studies evaluating the use of. Interferon-gamma release assay (IGRA) Whole blood: 1 ml directly into each of the four blood collection tubes. Total volume 4 ml. · QuantiFERON Nil control (grey cap) · QuantiFERON TB1 tube (green cap) · QuantiFERON TB2 tube (green cap) · QuantiFERON Mitogen control (purple cap

Interferon-γ Release Assays. IGRAs are ex vivo blood tests that detect interferon-γ (INF-γ) release from a patient's CD4+ T lymphocytes after stimulation by antigens found on the M tuberculosis complex (which includes M bovis, Mycobacterium africanum, Mycobacterium microti, and Mycobacterium canettii).Two IGRAs are available commercially: the QuantiFERON-TB Gold In-Tube assay (QFT. VRL Now Offering Interferon-γ Release Assay (IGRA) IGRA is the preferred method of early detection of M. tuberculosis. The TB blood test (IGRA) measures T cell-mediated immune response (the release of Interferon gamma, IFN-γ) by mixing Mycobacterium antigens with whole blood in vitro. Detect it early TB Gamma Interferon Release Assay (Quantiferon) General information This test measures gamma interferon produced by T cells in response to mycobacterial peptides Specimen transport: Samples should reach the laboratory within four hours of being drawn. Samples are not accepted at the weekend

More Info on Interferon gamma release assay Interferon-release assays (IGRAs) represents the advances in tuberculosis immunology and evolutionary biology. IGRAs were intended to replace tuberculin skin test (TST) for the diagnosis of latent tuberculosis infection because of their logistical advantages and enhanced specificity over TST Interferon ‐gamma release assays (IGRAs) provide a new diagnostic method for Mycobacterium tuberculosis (TB) infection. However, the diagnostic value of IGRAs for extrapulmonary TB (EPTB) has not been clarified. We searched several databases and selected papers with strict inclusion criteria, evaluated the evidence of commercially available IGRAs (QuantiFERON ® ‐TB Gold QFT‐G or QFT. Interferon-gamma release assays (IGRAs) are new immunologic diagnostic tools for TB based on detection of a T-cell immune response to the TB antigens, which include early secretary antigen target (ESAT-6), culture filtrate protein (CFP-10) and a third antigen, TB7.7 (included in the newer version of the QTF Gold test in vitro)

Interferon gamma release assays: principles and practice - ScienceDirec

Interferon-gamma release assay testing for SARS-CoV-2 was positive on day nineteen, demonstrating robust T-cell mediated response despite lack of antibody-mediated response. View. Show abstract.

QuantiFERON-TB Gold - QuantiFERO

  1. Many translated example sentences containing interferon gamma release assay - French-English dictionary and search engine for French translations
  2. The utility of an interferon gamma release assay for diagnosis of latent tuberculosis and disease in children: a systematic review and meta-analysis. Pediatr Infect Dis J 2011;30:1-7. Chiappini E, Bonsignori F, Accetta G, dkk. Interferon gamma release assay for the diagnosis of Mycobacterium tuberculosis infection in children: a literature review
  3. BackgroundAdaptive immune responses to structural proteins of the virion play a crucial role in protection against coronavirus disease 2019 (COVID-19). We therefore studied T cell responses against multiple SARS-CoV-2 structural proteins in a large cohort using a simple, fast, and high-throughput approach.MethodsAn automated interferon gamma release assay (IGRA) for the Nucleocapsid (NC.
  4. The Ministry of Defense conducted a contact investigation of all members who had come into contact with the infected members. The purpose of this study was to verify the efficacy of the TB screening protocol used in this investigation. A total of 884 subjects underwent interferon-gamma release assay (IGRA) and chest X-ray

Interferon-gamma release assay levels and risk of progression to active tuberculosis

  1. Of two interferon-gamma release assays, T-SPOT.TB was more sensitive than QFT-GIT in diagnosing active TB, but both were insufficiently sensitive for ruling out active TB in routine UK clinical practice
  2. This study was carried out at Severance Hospital, a tertiary hospital in South Korea with 2442 beds. The study subjects were 2228 HCWs who did not have any previous screening records of tuberculin skin tests (TSTs) and interferon-gamma release assays (IGRAs) or histories of tuberculosis
  3. 오늘은 IGRA (Interferon gamma release assay) 검사에 대해서 알아보도록 하겠습니다. IGRA의 이름을 그대로 살펴보면, 인터페론 감마의 방출량을 측정하는 검사법입니다. 이는 결핵처럼 세포 매개 면역을 일으키는 질환의 진단에 도움이 될 수 있습니다. 결핵균에 노출될.
  4. To study the use of interferon-gamma release assay (IFN-γ) (IGRAs) as a diagnostic test for tuberculosis (TB)-associated uveitis (TAU). Prospective cohort study. Consecutive new patients (n=162.
  5. Recently, novel in vitro assays termed T cell interferon-gamma release assay (TIGRA) have become available that are based on the detection of interferon-gamma (IFN-gamma) production in T cells or supernatants after stimulation with highly specific antigens of M. tuberculosis
  6. This can be done using an interferon-gamma (IFN-γ) release assay (IGRA), which includes antigenic stimulation of blood lymphocytes, followed by measurement of the release of IFN-γ. Interferon-γ is a commonly used cytokine biomarker of cellmediated immunity for the diagnosis of tuberculosis (TB) and is considered vital to a host's protection against intracellular pathogens such as M. bovis.

Interferon-gamma release assay for diagnosing Mycobacterium tuberculosis infections in

Interferon-Gamma Release Assay Performance in Pulmonary and Extrapulmonary Tuberculosi

Video Abstract OBJECTIVES: The tuberculin skin test (TST) has been preferred for screening young children for latent tuberculosis infection (LTBI) because of concerns that interferon-γ release assays (IGRAs) may be less sensitive in this high-risk population. In this study, we compared the predictive value of IGRAs to the TST for progression to tuberculosis disease in children, including. Obtaining an Interferon Gamma Release Assay (IGRA) Pre-Export Test for Rodeo Cattle of the breeds Corriente, Brahman Texas Longhorns, and American Bucking Bulls (ABBI)* Guidance For Accredited Veterinarians For exportations of U.S. cattle of the breeds Corriente, Brahman, Texas Longhorn, and America Both assays measure gamma interferon production following either whole-blood (QFT-GIT) or mononuclear cell (T-Spot) incubation with antigens derived from M. tuberculosis. These procedures have been given the common name of interferon gamma release assays (IGRAs)

Interferon-γ release assays (IGRAs) are now established for the immunodiagnosis of latent infection with Mycobacterium tuberculosis in many countries. However, the role of IGRAs for the diagnosis of active tuberculosis (TB) remains unclear. Following preferred reporting items for systematic reviews and meta-analyses (PRISMA) and quality assessment of diagnostic accuracy studies (QUADAS. Richtlijn IGRA, Definitieve versie april 2011 Page 1 RICHTLIJN Interferon Gamma Release Assays bij de diagnostiek van tuberculose 2010 IGRA-werkgroep Commissie voor Praktische Tuberculosebestrijding Samenstelling werkgroep Dhr. R. van Altena, longarts UMCG, consulent klinische tuberculose KNCV Tuberculosefond

gamma release assays (IGRAs), based on the principle that the T-cells of individuals who have acquired TB infection respond to re-stimulation with Mycobacterium tuberculosis -specific antigens by secreting interferon gamma (IFN - γ) interferon-gamma release assays (IGRAs) for the diagnosisof latent tuberculosis (TB) infection and active TB. T he panel expressed that IGRAs should not replace the existing standard diagnostic methods for the diagnosis of active TB and that a negative IGRA result does not exclude active TB disease

Interferon-gamma Release Assay Request PD

Both the assays used in this case, as for other IFN-γ-release assays, are immune-based methods that indicate a cellular immune response to a recent or previous encounter with M. tuberculosis. Objective . To reveal the relationship between interferon-gamma release assay (IGRA) test (Standard ETB-Feron ELISA (TBF)) results performed within 12 months before the COVID-19 pandemic and the frequency of COVID-19 infections and the severity of COVID-19. Methods . The retrospective TBF test results and contact information of 684 patients aged over 18 years who underwent TBF testing between.

T cell expansion with increased Interferon Gamma (IFN-γ) release. Note that increased IFN-γ is also an early and prominent element of CRS I.FN -γ, along with IL-6, IL-10 and TNF-alpha are the core cytokines involved in CRS (2). IFN-γ activates macrophages which secrete excessive amounts of other cytokines such as IL-6, TNFα and IL-10 Interferon-γ (IFN-γ) release assays rely on the fact that T-lymphocytes will release IFN-γ when exposed to specific antigens. These tests are mostly developed for the field of tuberculosis diagnosis, but in theory, may be used in the diagnosis of other diseases which rely on cell-mediated immunity, e.g. cytomegalovirus and leishmaniasis The IFN-gamma release assay performed equally well in each trimester of pregnancy with comparable results to nonpregnant females. Interferon-gamma release assays are much more specific, at least as sensitive, and may be a better predictor of disease progression than the tuberculin skin test Interferon-Gamma Release Assays versus Tuberculin Skin Testing for the Diagnosis of Latent Tuberculosis Infection: An Overview of the Evidence. A. Trajman, 1 , 2 ,* R. E. Steffen, 3 and D. Menzies 2. A. Trajman. 1 Gama Filho University, 20740-900 Rio de Janeiro, RJ, Brazil

Interferon gamma release assay test (ELISPOT TB) was positive, providing further support for a diagnosis of tuberculosis. The latest in this line is the Interferon Gamma Release Assay (IGRA) test which involves taking a blood sample to test for dormant as well as active TB. QFT-Plus builds on the foundation of QuantiFERON-TB Gold, the third. Interferon gamma release assay. Tine test. Interferon gamma release assay. Tine test. Share. This will create an email alert. Stay up to date on result for:. Interferon gamma release assays (IGRA) have similar limitations in those with HIV. Tuberculosis - Wikipedia The role of IFN-γ tests is undergoing constant review and various guidelines have been published with the option for revision as new data becomes available.CDC:MMWR Health Protection Agency:UK Latent tuberculosis - Wikipedi

Interferon Gamma Release Assays (IGRAs) - YouTub

The interferon-gamma release assay (IGRA) is used to diagnose cases of feline mycobacteriosis, but the use of serial testing to monitor treatment responses has not been evaluated in this species. From a population of cats that underwent IGRA testing for diagnostic investigation, individuals were identified with a pre- and end-of-treatment IGRA that passed control thresholds Interferon-gamma-release assays (IGRAs) are alternatives to the tuberculin skin test (TST). A recent meta-analysis showed that IGRAs have high specificity, even among populations that have. Alternative Meanings. IGRA - Interferon-Gamma Release Assay. IGRA - Integrated Global Radiosonde Archive. IGRA - International Green Roof Association. IGRA - IFN-Gamma Release Assay. IGRA - Indian Gaming and Regulatory Act. 32 other IGRA meanings

Interferon-γ Release Assay for Accurate Detection of Severe Acute Respiratory

Background . In a country like India, where the prevalence of tuberculosis is very high, the role of screening tools for detection of latent tuberculosis infection (LTBI) like TST and IGRA is still unclear, especially in inflammatory bowel disease (IBD) patients. Our study is aimed at comparing the interferon-gamma release assay (IGRA) and tuberculin skin test (TST) to determine the prevalence. Interferon-γ release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am. J. Respir. Crit. Care Med. [Epub ahead of print.] doi: Crossref. Google Scholar. 87. Slater M, Welland G, Pai M, Parsonnet J, and Banaei N. 2013 Position statement on interferon-γ release assays in the detection of latent tuberculosis infection. Commun Dis Intell 2012;36(1):125-131. Mazurek M, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection—United States, 2010 The interferon-gamma release assay (IGRA), a new diagnostic using Mycobacterium tuberculosis-specific antigens has been introduced in response to these needs. In this review, published findings on the performance of the QuantiFERON-TB (QFT), one of the IGRA formats, are summarized and discussed Interferon-gamma (IFNγ) release assay (IGRA) was performed according to Pesciaroli et al. on whole blood samples collected in heparinized tubes by venipuncture from each animal before SICCT was performed. Four aliquots of blood (1.5 mL) were separately stimulated in a 24-flat-bottomed-well plate with a-PPD (10 μg/mL.

Frontiers Species-Specific Interferon-Gamma Release Assay for the Diagnosis of

the interferon gamma release assay and people in rural and remote settings who may have been exposed to tuberculosis. Where possible, retrieval was limited to the human population. The search was also limited to English-language documents published between January 1, 2015 and July 26, 2020 Interferon (IFN)-γ release assays (IGRAs) are in vitro immune tests that have been introduced in recent years as an alternative to the TST for the diagnosis of LTBI. IGRAs are based on the detection of a T-cell immune response towards M. tuberculosis complex specific antigens (early secretory antigenic target (ESAT)-6, culture filtrate protein (CFP)-10 and/or TB7.7)

How to use: interferon γ release assays for tuberculosisInterferon Gamma Release Assays (IGRAs) - YouTubeQuantiFERON-TB Gold – QuantiFERONThe T-SPOTRecent Developments in Tuberculosis and Tuberculosis-HIVLatent Tuberculosis Infection – Important Developments inChallenges in Screening for Latent TB in InflammatoryAre Chimpanzees Really As Strong As They're Made Out to Be